Alzheimer's Therapeutics Market Forecasts to 2030 – Global Analysis By Product (Cholinesterase Inhibitors, N -Methyl-D-Aspartate (NMDA) Receptor Antagonists and Other Products), End User (Hospital Pharmacies, Retail Pharmacies and Other End Users) and By

Alzheimer's Therapeutics Market Forecasts to 2030 – Global Analysis By Product (Cholinesterase Inhibitors, N -Methyl-D-Aspartate (NMDA) Receptor Antagonists and Other Products), End User (Hospital Pharmacies, Retail Pharmacies and Other End Users) and By Geography

According to Stratistics MRC, the Global Alzheimer’s Therapeutics Market is accounted for $7.3 billion in 2023 and is expected to reach $14.5 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Alzheimer's disease is a neurological disorder that causes the brain to shrink (atrophy) and brain cells to die. It is the most common cause of dementia that leads to continuous decline in thinking, behavioral and social skills that affects the ability of a person to function independently. The early signs of the disease include forgetting recent events or conversations.

According to the Journal of the Alzheimer’s Association, In the United States, around 1 in 9 people which comprised 10.7% of the people aged 65 and older are having Alzheimer’s dementia.

Market Dynamics

Driver

Growing demand for effective treatments

As the global population ages, the prevalence of Alzheimer's disease is increasing, creating a pressing need for therapies that can slow down its progression or alleviate its symptoms. This demand has spurred increased research and investment in the development of new drugs and therapies. Pharmaceutical companies are actively seeking innovative approaches, such as disease-modifying drugs and precision medicine, to address this unmet medical need. Additionally, the focus on improving the quality of life for Alzheimer's patients has driven the market for supportive care products and services, making it a lucrative and evolving sector in the healthcare industry.

Restraint

High cost of research and development for Alzheimer's drugs

Developing effective treatments for Alzheimer's disease is an intricate and time-consuming process, often involving lengthy clinical trials and rigorous regulatory requirements. The failure rate in Alzheimer's drug development is notably high, leading to substantial financial investments without guaranteed success. These elevated R&D costs can discourage pharmaceutical companies from pursuing Alzheimer's drug development, limiting the number of potential treatments. Moreover, these expenses can subsequently result in high medication prices, which may pose affordability challenges for patients and healthcare systems, thus further hindering access to these crucial therapies.

Opportunity

Development of innovative approaches such as precision medicine and gene therapy

Precision medicine tailors treatments to an individual's genetic and molecular profile, potentially leading to more effective and personalized therapies. Gene therapy, on the other hand, aims to address the root causes of Alzheimer's by targeting specific genetic mutations or aberrant proteins. These groundbreaking techniques hold the potential to modify the course of the disease, offering hope for both prevention and treatment. As research in these areas progresses, they offer the prospect of more precise, impactful, and potentially curative interventions, marking a significant step forward in the fight against Alzheimer's.

Threat

The lengthy and complex regulatory approval process

Developing and bringing new Alzheimer's drugs to market is a time-consuming and resource-intensive endeavor, often spanning over a decade. The stringent regulatory requirements, including extensive clinical trials and rigorous safety evaluations, significantly extend the time and cost required for approval. The high attrition rate in Alzheimer's drug development further exacerbates this challenge. Delays in obtaining regulatory clearance not only deter pharmaceutical companies but also hinder patient access to potentially life-changing treatments.

Covid-19 Impact

The COVID-19 pandemic has had a multifaceted impact on the Alzheimer's market. On one hand, it disrupted clinical trials and research efforts aimed at developing new Alzheimer's treatments, causing delays and setbacks. Additionally, the redirection of healthcare resources towards pandemic response strained the care and support available for Alzheimer's patients. Social isolation measures exacerbated cognitive decline and mental health issues among this vulnerable population. On the other hand, the pandemic highlighted the need for innovative remote monitoring and telehealth solutions for Alzheimer's patients. It also underscored the importance of preparedness in long-term care facilities.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The cholinesterase inhibitors segment is expected to have lucrative growth. These medications, including drugs like Donepezil, Rivastigmine, and Galantamine, are designed to alleviate cognitive symptoms by enhancing the levels of acetylcholine, a neurotransmitter in the brain. They provide temporary relief from memory and cognitive impairments, improving the quality of life for Alzheimer's patients. Cholinesterase inhibitors have been a mainstay of treatment, though they do not offer a cure. With the increasing prevalence of Alzheimer's, the market for these drugs continues to grow, alongside ongoing research to develop more effective and targeted treatments for this devastating neurodegenerative disease.

The drug stores segment is expected to have the highest CAGR during the forecast period

The drug stores segment is anticipated to witness the fastest CAGR growth during the forecast period. These retail outlets offer a wide range of pharmaceuticals, including cholinesterase inhibitors and memantine, which are commonly prescribed to manage Alzheimer's symptoms. Additionally, drug stores provide over-the-counter products such as supplements and medical supplies, crucial for Alzheimer's patients and their caregivers. They often serve as a valuable resource for families seeking information and support for managing the disease. With the rising prevalence of Alzheimer's, drug stores are increasingly focused on providing specialized services and products tailored to the unique needs of this patient population, thus contributing significantly to Alzheimer's care and treatment.

Region with largest share

During the forecast period, it is expected that the North America Alzheimer’s Therapeutics market will continue to hold a majority of the market share due to its dynamic and rapidly evolving sector within the healthcare industry. It encompasses a range of pharmaceuticals, biologics, and emerging therapies aimed at managing and treating Alzheimer's disease, a prevalent neurodegenerative condition. With a growing aging population and increasing awareness of Alzheimer's, the market is witnessing significant investments in research and development. Key players are working on innovative approaches, including disease-modifying drugs and precision medicine, to address the complex nature of Alzheimer's.

Region with highest CAGR

Asia Pacific is projected to have the highest CAGR over the forecast period. With a rapidly aging population and improving healthcare infrastructure, the prevalence of Alzheimer's is on the rise. Countries like Japan, China, and South Korea are investing heavily in research and development for Alzheimer's treatments, leading to a competitive pharmaceutical market. However, challenges such as underdiagnosis, limited awareness, and varying healthcare systems across the region persist. Regulatory hurdles and cultural stigmas also impact patient care and access to innovative therapies. Nonetheless, the Asia Pacific Alzheimer's market holds significant growth potential, driven by a pressing need for effective treatments in the face of this escalating public health concern.

Key players in the market

Some of the key players in Alzheimer’s Therapeutics Market include Cipla Ltd., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd, AbbVie, Inc., Eisai Co., Ltd., Adamas Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., H. Lundbeck A/S, Johnson & Johnson Services, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., TauRx Pharmaceuticals Ltd., Lannett Inc., Lupin Ltd and Macleods Pharmaceuticals Ltd.

Key Developments

In March 2023, Biogen Inc. and Eisai Co., expanded their collaboration to find therapeutics treatments of the disease.

In December 2022, Kashiv Specialty Pharmaceuticals is acquired by Amneal. Amneal obtained access to the pipeline of complex generics and branded 505(b)2 medicines through this arrangement.

In May 2022, Amneal completed the acquisition of Kashiv Specialty Pharmaceuticals. Through this acquisition, Amneal gained the pipeline of 505(b)2 branded products and complex generics.

Products Covered
• Cholinesterase Inhibitors
• N -Methyl-D-Aspartate (NMDA) Receptor Antagonists
• Combination Drug
• Other Products

End Users Covered
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies
• Other End Users

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements